Precision medicine requires success in two intertwined aspects: precision therapy and personalized medicine. Precision therapy is being able to effectively treat the right disease; to have therapies that target for the correct pathological pathways.  Personalized medicine requires diagnosing a specific individual’s disease based on accurate assessment their complex health and pathological status. Our underlying premise is that an individual’s baseline proteome reflects their past and present and thus, will dictate their future health and disease. Thus, the crux of precision medicine will be the identification and precise quantification of proteins and their modified forms. We will present data to support the notion that an individual’s baseline proteome dictates the manifestation of their disease, its progression and their response to therapy. This concept has driven decision-making processes around new drug trials that take into account altered pathological proteomes.  Furthermore, this work has led us to consider the need for continuous patent-centric biomarker analysis at the population level. We will share our work on developing technical pipelines for health and pathological discovery and targeted proteomic analysis that reduces the barriers around gender, age and social economic status. We have begun down this path with production of system suitability and quality control measures, development of quantitative small and large multiplex assays and will discuss the remaining challenges involved and requirement for population-scale proteomics.

Learning Objectives:

• Understand the underlying premise that an individual’s baseline proteome reflects their past and present and thus, will dictate their future health and disease
• See data to support the notion that an individual’s baseline proteome dictates the manifestation of their disease, its progression and their response to therapy